Immuneering Corporation Marketable Securities, Unrealized Gain (Loss)
Immuneering Corporation (IMRX) reported Marketable Securities, Unrealized Gain (Loss) of $18.89 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-06.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2023-03-06
- Immuneering Corporation marketable securities, unrealized gain (loss) for the quarter ending 2022-12-31 was $112.35K.
- Immuneering Corporation marketable securities, unrealized gain (loss) for the quarter ending 2022-09-30 was $39.09K.
- Immuneering Corporation marketable securities, unrealized gain (loss) for the quarter ending 2022-06-30 was -$14.17K.
- Immuneering Corporation marketable securities, unrealized gain (loss) for the quarter ending 2022-03-31 was -$118.39K.
- Immuneering Corporation marketable securities, unrealized gain (loss) for fiscal 2022 was $18.89K.
- Immuneering Corporation marketable securities, unrealized gain (loss) for fiscal 2021 was -$49.01K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2022-12-31 | $112.35K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $151.44K derived: sum of 2 quarters · filed 2023-03-06 | $137.28K derived: sum of 3 quarters · filed 2023-03-06 | $18.89K 10-K · filed 2023-03-06 |
| 2022-09-30 | $39.09K 10-Q · filed 2022-11-10 | $24.92K derived: sum of 2 quarters · filed 2022-11-10 | -$93.46K 10-Q · filed 2022-11-10 | -$137.72K derived: sum of 4 quarters · filed 2023-03-06 |
| 2022-06-30 | -$14.17K 10-Q · filed 2022-08-10 | -$132.55K 10-Q · filed 2022-08-10 | -$176.81K derived: sum of 3 quarters · filed 2023-03-06 | -$181.56K derived: sum of 4 quarters · filed 2023-03-06 |
| 2022-03-31 | -$118.39K 10-Q · filed 2022-05-10 | -$162.64K derived: sum of 2 quarters · filed 2023-03-06 | -$167.40K derived: sum of 3 quarters · filed 2023-03-06 | |
| 2021-12-31 | -$44.26K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$49.01K derived: sum of 2 quarters · filed 2023-03-06 | -$49.01K 10-K · filed 2023-03-06 | |
| 2021-09-30 | -$4.75K 10-Q · filed 2022-11-10 | -$4.75K 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |